Audio Recap: HABP/VABP
HABP/VABP and Gram-Negative Resistance: Pathways to Early Effective Therapy

Released: March 15, 2022

Expiration: March 14, 2023

Lilian Abbo
Lilian Abbo, MD, MBA, FIDSA
Keith S. Kaye
Keith S. Kaye, MD, MPH
Jason M. Pogue
Jason M. Pogue, PharmD

Activity

Progress
1
Course Completed

In this episode, Keith S. Kaye, MD, MPH; Lilian Abbo, MD, FIDSA; and Jason M. Pogue, PharmD, discuss HABP/VABP and gram-negative resistance including:

  • Epidemiology and burden of nosocomial bacterial pneumonia
  • Patient-specific risk factors for MDR pathogens
  • Improving outcomes with the use of antibiograms
  • Recommended empiric therapy for clinically suspected VABP
  • Antimicrobial resistance in HABP/VABP
  • Algorithms for gram-negative organism antibiotic-susceptibility testing
  • Using rapid diagnostic tests for HABP/VABP
  • New antimicrobial agents for MDR gram-negative infections with discussion of the 2021 IDSA guidance, and the following studies:
    • ASPECT-NP: ceftolozane/tazobactam vs meropenem
    • REPROVE: ceftazidime/avibactam vs meropenem
    • RESTORE-IMI-1 imipenem/cilastatin/relebactam vs colistin + imipenem
    • RESTORE-IMI-2: imipenem/cilastatin/relebactam vs piperacillin/tazobactam
    • APEKS-NP: cefiderocol vs meropenem
    • CREDIBLE-CR: cefiderocol vs best available therapy